ARMO BioSciences Competitors and Similar CompaniesClear all
ARMO BioSciences's competitors and similar companies include Intra-Cellular Therapies, Histocell, Kanghong Pharmaceutical and TCM Biotech.
 ARMO BioSciences ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. |  Intra-Cellular Therapies Intra-Cellular Therapies develops drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the CNS. |  Histocell Histocell is a biopharmaceutical company focused on the development, manufacturing, and commercialization of medical devices, active ingredients, and cell therapy drugs for regenerative medicine. |  Kanghong Pharmaceutical Kanghong Pharmaceutical (成都康弘药业集团股份有限公司) is a company that produces and sells biological products. |  TCM Biotech TCM Biotech (泰宗生物科技股份有限公司, also known as Taizong Biotechnology) is a biotech company that specializes in the research and development of drugs. | |
Founding Date | Founding Date 2013 | Founding Date 2002 | Founding Date 2011 | Founding Date 1996 | Founding Date 1998 |
Type | Type Subsidiary | Type Public | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Redwood City, US HQ | Locations New York, US HQ | Locations Derio, ES HQ Larrabetzu, ES | Locations Cheng Du Shi, CN HQ | Locations HQ |
Employees | Employees 257% decrease | Employees 330352% increase | Employees 365% decrease | Employees 4,462 | Employees N/A |
Valuation ($) | Valuation ($) N/A | Valuation ($) 8.1 b | Valuation ($) N/A | Valuation ($) 2.5 b | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $680.9m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) ¥4.5b (FY, 2025) | Revenue (est.) NT$685.5m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods ¥465.4m (FY, 2025) | Cost of goods NT$345m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit ¥4.1b (FY, 2025) | Gross profit NT$340.7m (FY, 2025) |
Net income | Net income ($42.4m) (FY, 2017) | Net income ($74.7m) (FY, 2024) | Net income N/A | Net income ¥1.1b (FY, 2025) | Net income NT$19.2m (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 167m | Total funding raised $ 225.3m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Intra-Cellular Therapies
HQ
New York, US
Employees
330
Intra-Cellular Therapies develops drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the CNS.
View companyHistocell
HQ
Derio, ES
Employees
36↓ 5% decrease
Histocell is a biopharmaceutical company focused on the development, manufacturing, and commercialization of medical devices, active ingredients, and cell therapy drugs for regenerative medicine.
View companyKanghong Pharmaceutical
HQ
Cheng Du Shi, CN
Employees
4,462
Kanghong Pharmaceutical (成都康弘药业集团股份有限公司) is a company that produces and sells biological products.
View companyTCM Biotech
HQ
TCM Biotech (泰宗生物科技股份有限公司, also known as Taizong Biotechnology) is a biotech company that specializes in the research and development of drugs.
View company